| Old Articles: <Older 23181-23190 Newer> |
|---|
 |
The Motley Fool
May 14, 2007
Jeremy MacNealy |
Fool on Call: Disney's Magical Distribution Model From DVDs to iTunes, the media and entertainment group drives growth from multiple platforms. Investors, take note.   |
The Motley Fool
May 14, 2007 |
Urban Outfitters' Perfect Fit: Fool by Numbers The apparel retailer released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 14, 2007
Rich Smith |
Buddy, Can You Spare a Carrot? LCA-Vision missed earnings last week, for the first time in 18 quarters of reporting -- and it did so in a big way. Investors, take note. |
The Motley Fool
May 14, 2007
Brian Lawler |
Onyx Rocks The oncology-focused biotech announces first-quarter financial results. Investors, take note. |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
The Motley Fool
May 14, 2007
David Lee Smith |
OpenTV's Steadily Weakening Signal OpenTV, which once traded in the stratosphere, clearly has seen its best days. So, should investors being buying shares by the bucketful? |
The Motley Fool
May 14, 2007
Brian Lawler |
Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note. |
The Motley Fool
May 14, 2007
Jeff Hwang |
The Future of the Mississippi Gulf Coast Reporting from the Southern Gaming Conference on Biloxi's future. Investors, take note: 1. 30,000 hotel rooms... 2. 600,000 square feet of convention space... 3. Increase air travel capacity... etc. |
The Motley Fool
May 14, 2007
Rick Aristotle Munarriz |
Skype Me, Sam Walton Wal-Mart stocks Skype-friendly products. Don't assume customers will call. But investors should see that it's another step forward toward ubiquity, even if the cash registers aren't initially kind. |
The Motley Fool
May 14, 2007
Brian Orelli |
Little Product, Big Profits Abraxis Bioscience reports increased sales of its nano-sized drug. Investors, take note. |
| <Older 23181-23190 Newer> Return to current articles. |
